eoadjuvant combined chemotherapy with gemcitabine, cisplatin and zoledronic acid against muscle invasive bladder cancer
Not Applicable
- Conditions
- bladder cancer
- Registration Number
- JPRN-UMIN000003146
- Lead Sponsor
- Department of Urology, Graduate School of Biomedical Sciences Hiroshima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
overt infection. fever(>38 degree) catastrophic complication active double cancer asymptomatic brain metastases pleural effusion pericarium varicella moror parallysis or peripheral nervedisorder drug sensitivity pregnant woman, and have possibility
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method safety survival(over all survival, progression free survival)